CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: June 11, 2026 , by Moore David Scott .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Moore David Scott | Director | Buy | 21,700 | $11.53 | $250.2K | 21,700 | |
| MILLER RICHARD A MD 2 fills | President and CEO | Buy | 6,932 | $12.04 | $83.5K | 1,195,035 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.